GKOS - Conference and earnings call announcements

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at 1:00 p.m. ET in Chicago, IL Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 a.m. ET in New York City, NY Truist MedTech Conference on Tuesday, June 16, 2026, at 9:20 a.m. ET in Boston, MA A live an

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therap

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 10:15 a.m. ET in Palm Beach, FL Stifel Healthcare Conference on Wednesday, November 12, 2025, at 1:20 p.m. ET in New York City, NY Stephens Annual Investment Conference on Tuesday, November 18, 2025, at 10:00 a.m. CT in Nashville, TN BTIG Ophthalmology Day on Monday, December 1, 2025 (virtual) Citi Global Healthc

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 12:30 p.m. ET William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025, at 1:40 p.m. ET in Chicago, IL Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. ET in New York City, New York A live and archived webcast for these events, where applicable, will be available in the

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel the

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY Stephens Annual Investment Conference on Wednesday, November 20, 2024, at 10:00 a.m. ET in Nashville, TN BTIG Ophthalmology Day on Monday, December 2, 2024, at 4:40 p.m. ET (Virtual) Piper Sandler Annual Healthcare Conference on Wednesday, December 4, 2024, at 1:00 p.m. ET in New York City

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 12:45 p.m. ET in Boston, MA Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 12:20 p.m. ET in New York City, NY A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024, at 1:40 p.m. ET in Chicago, IL Truist MedTech Conference on Tuesday, June 18, 2024, at 12:45 p.m. ET in Boston, MA A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel ther

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m. ET in New York City. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the trea

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 12:45 p.m. ET in Boston, MA. A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 10:40 a.m. CT in Chicago, IL. A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Citi Healthcare Conference on Wednesday, March 1, 2023, at 1:15 p.m. ET in New York City. A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal di

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 41st Annual J.P Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Annual Investment Conference on Wednesday, November 16, 2022, at 2:00 p.m. CT in Nashville, TN. A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glauc

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:45 p.m. ET in Boston, MA. A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, co

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, 2022, at 8:40 a.m. CT in Chicago, IL. A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of

Conference Call and Webcast Scheduled for 1:30 p.m. PDT Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2021 financial results after the market close on Thursday, August 5, 2021. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 5, 2021. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647-689-4107

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2021. Key highlights include: Net sales growth of 23% to $68.0 million in Q1 2021, compared to $55.3 million in Q1 2020. Glaucoma net sales of $53.7 million and Corneal Health net sales of $14.3 million in Q1 2021. Gross margin of approximately 76% and non-GAAP gross margin of approximately 84% in Q1 2021. Operating expenses of $63.1 million and non-GAAP operating expenses of $61.8 million in Q1 2021. "Our strong start to

Conference Call and Webcast Scheduled for 1:30 p.m. PDT Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647-689-4107 (Inter

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020. Key highlights include: Net sales of $73.2 million in Q4 2020, compared to $65.8 million in Q4 2019. Glaucoma net sales of $58.4 million and Corneal Health net sales of $14.9 million in Q4 2020. Gross margin of approximately 73% and non-GAAP gross margin of approximately 83% in Q4 2020. Operating expenses of $65.0 million and non-GAAP operating expense

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2020 financial results after the market close on Thursday, February 25, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 25, 2021. A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647